Search research articles
Contact Us
Filters
Showing results (1-10 of 131) with videos related to
Page
of 14
Sort By:
JCO Precision Oncology
|
October 16, 2025
Reply to: Epidermal Growth Factor Receptor Amplification: Passenger or Partner? Rethinking Biomarkers in Postosimertinib Strategy
Jonathan W Riess
Current Treatment Options in Oncology
|
June 27, 2020
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Justin A Chen, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 20, 2012
Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer
Jonathan W Riess, Joel W Neal
Cancer Treatment and Research
|
August 19, 2016
Multidisciplinary Care
Megan E Daly, Jonathan W Riess
Journal of Thoracic Disease
|
July 10, 2020
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Justin A Chen, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer
Jonathan W Riess, Joel W Neal
Clinical Lung Cancer
|
February 18, 2014
Left behind? Drug discovery in extensive-stage small-cell lung cancer
Jonathan W Riess, Primo N Lara
Clinical Advances in Hematology & Oncology : H&O
|
June 19, 2012
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
Jonathan W Riess, Heather A Wakelee
Expert Review of Anticancer Therapy
|
December 7, 2019
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
Collin M Blakely, Jonathan W Riess
Journal of Thoracic Disease
|
October 29, 2013
The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era
Zarnie Lwin, Jonathan W Riess, David Gandara
Page
of 14
Search research articles
Search
Showing results (1-10 of 131) with videos related to
Sort By:
Page
of 14
JCO Precision Oncology
|
October 16, 2025
Reply to: Epidermal Growth Factor Receptor Amplification: Passenger or Partner? Rethinking Biomarkers in Postosimertinib Strategy
Jonathan W Riess
Current Treatment Options in Oncology
|
June 27, 2020
Optimal Management of Patients with Advanced NSCLC Harboring High PD-L1 Expression and Driver Mutations
Justin A Chen, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 20, 2012
Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer
Jonathan W Riess, Joel W Neal
Cancer Treatment and Research
|
August 19, 2016
Multidisciplinary Care
Megan E Daly, Jonathan W Riess
Journal of Thoracic Disease
|
July 10, 2020
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Justin A Chen, Jonathan W Riess
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 19, 2011
Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer
Jonathan W Riess, Joel W Neal
Clinical Lung Cancer
|
February 18, 2014
Left behind? Drug discovery in extensive-stage small-cell lung cancer
Jonathan W Riess, Primo N Lara
Clinical Advances in Hematology & Oncology : H&O
|
June 19, 2012
Metastatic non-small cell lung cancer management: novel targets and recent clinical advances
Jonathan W Riess, Heather A Wakelee
Expert Review of Anticancer Therapy
|
December 7, 2019
Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
Collin M Blakely, Jonathan W Riess
Journal of Thoracic Disease
|
October 29, 2013
The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era
Zarnie Lwin, Jonathan W Riess, David Gandara
Page
of 14